Acute Myelogenous Leukemia: Genetics, Biology and Therapy by Lalitha NagarajanAcute Myelogenous Leukemia: Genetics, Biology and Therapy by Lalitha Nagarajan

Acute Myelogenous Leukemia: Genetics, Biology and Therapy

EditorLalitha Nagarajan

Hardcover | November 18, 2009

Pricing and Purchase Info


Earn 1,945 plum® points

Prices and offers may vary in store


In stock online

Ships free on orders over $25

Not available in stores


Acute myelogenous leukemia (AML), is the most common form of leukemia in adults. AML is a deadly form of malignancy, the prognosis for which has not improved in the last two decades. More importantly, it is a malignancy that is seen in older adults, therefore the number of cases is likely to rise as the population ages. Over the past 15 years, genetic mechanisms underlying AML have begun to unfold. Additional research in this area has helped identify key components and characteristics. Consequently, targeted therapy of AML is receiving much attention. It is the hope of researchers that as with chronic myelogenous leukemia (CML), and the drug, Gleevec, a targeted therapy for AML will be discovered.
Lalitha Nagarajan is an Associate Professor, Department of Molecular Genetics, The University of Texas, M.D. Anderson Cancer Center, Houston, Texas. 
Title:Acute Myelogenous Leukemia: Genetics, Biology and TherapyFormat:HardcoverDimensions:289 pagesPublished:November 18, 2009Publisher:Springer New YorkLanguage:English

The following ISBNs are associated with this title:

ISBN - 10:0387692576

ISBN - 13:9780387692579

Look for similar items by category:


Table of Contents

The Leukemia Stem Cell.- Epigenetic Mechanisms in AML - a Target for Therapy.- Chromosomal Translocations in AML: Detection and Prognostic Significance.- Chromosomal Deletions in AML.- Genes Predictive of Outcome and Novel Molecular Classification Schemes in Adult Acute Myeloid Leukemia.- Receptor Tyrosine Kinase Alterations in AML - Biology and Therapy.- Lineage Specific Transcription Factor Aberrations in AML.- Pro-leukemic RUNX1 and CBFß Mutations in the Pathogenesis of Acute Leukemia.- Acute Myeloid Leukemia with Mutated Nucleophosmin (NPM1): Molecular, Pathological and Clinical Features.- MicroRNAs: New Players in AML Pathogenesis.- Murine Models of Human Acute Myeloid Leukemia.- AML and Apoptosis.- Acute Promyelocytic Leukemia, a Paradigm for Differentitation Therapy.- Immunotherapy of AML.- Therapy of Acute Myelogenous Leukemia in Adults.